{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:29:55Z","timestamp":1776086995225,"version":"3.50.1"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-17 CA008748"],"award-info":[{"award-number":["P30-17 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0448-1","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T14:30:01Z","timestamp":1542724201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Acquired resistance to immunotherapy in MMR-D pancreatic cancer"],"prefix":"10.1136","volume":"6","author":[{"given":"Zishuo Ian","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinru","family":"Shia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsofia K.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"issue":"6349","key":"448_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"issue":"3","key":"448_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017;7(3):264\u201376.","journal-title":"Cancer Discov"},{"issue":"12","key":"448_CR3","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7(12):1420\u201335.","journal-title":"Cancer Discov"},{"issue":"2","key":"448_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","volume":"46","author":"S George","year":"2017","unstructured":"George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity. 2017;46(2):197\u2013204.","journal-title":"Immunity"},{"issue":"9","key":"448_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"3","key":"448_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.4049\/jimmunol.174.3.1462","volume":"174","author":"CC Chang","year":"2005","unstructured":"Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol. 2005;174(3):1462\u201371.","journal-title":"J Immunol"},{"issue":"6","key":"448_CR7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","volume":"13","author":"Scott N. Gettinger","year":"2018","unstructured":"Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, et al. Clinical features and management of acquired resistance to PD-1 axis inhibitors in twenty-six patients with advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(6):831-9. https:\/\/doi.org\/10.1016\/j.jtho.2018.03.008 . Epub 2018 Mar 22.","journal-title":"Journal of Thoracic Oncology"},{"issue":"8","key":"448_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828\u201333.","journal-title":"J Immunother"},{"issue":"26","key":"448_CR9","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"4_suppl","key":"448_CR10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2018.36.4_suppl.217","volume":"36","author":"EM O\u2019Reilly","year":"2018","unstructured":"O\u2019Reilly EM, Oh D-Y, Dhani N, Renouf DJ, Lee MA, Sun W, et al. A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study. J Clin Oncol. 2018;36(4_suppl):217.","journal-title":"J Clin Oncol"},{"issue":"18","key":"448_CR11","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-06-0369","volume":"12","author":"N Hiraoka","year":"2006","unstructured":"Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423\u201334.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"448_CR12","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00262-011-1178-0","volume":"61","author":"MR Porembka","year":"2012","unstructured":"Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012;61(9):1373\u201385.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"448_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73(3):1128\u201341.","journal-title":"Cancer Res"},{"issue":"6","key":"448_CR14","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res. 2018;24(6):1326\u201336.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"448_CR15","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131.","journal-title":"N Engl J Med"},{"issue":"3","key":"448_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251\u201364.","journal-title":"J Mol Diagn"},{"issue":"4","key":"448_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"4","key":"448_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2310\/JIM.0b013e31824a4d79","volume":"60","author":"MB Wachsmann","year":"2012","unstructured":"Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med. 2012;60(4):643\u201363.","journal-title":"J Investig Med"},{"issue":"23","key":"448_CR19","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255\u201362.","journal-title":"N Engl J Med"},{"issue":"2","key":"448_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","volume":"88","author":"NP Restifo","year":"1996","unstructured":"Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88(2):100\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"448_CR21","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-16-3172","volume":"77","author":"M Donia","year":"2017","unstructured":"Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, et al. Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNgamma signaling. Cancer Res. 2017;77(17):4562\u20136.","journal-title":"Cancer Res"},{"issue":"1","key":"448_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/bjc.1995.18","volume":"71","author":"AE Taylor","year":"1995","unstructured":"Taylor AE, Nicolson VM, Cunningham D. Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment. Br J Cancer. 1995;71(1):92\u20136.","journal-title":"Br J Cancer"},{"issue":"4","key":"448_CR23","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934\u201349 e15.","journal-title":"Cell"},{"issue":"6832","key":"448_CR24","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107\u201311.","journal-title":"Nature"},{"issue":"11","key":"448_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991\u20138.","journal-title":"Nat Immunol"},{"issue":"12","key":"448_CR26","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1158\/1078-0432.CCR-17-0270","volume":"23","author":"ML Ascierto","year":"2017","unstructured":"Ascierto ML, Makohon-Moore A, Lipson EJ, Taube JM, McMiller TL, Berger AE, et al. Transcriptional mechanisms of resistance to anti-PD-1 therapy. Clin Cancer Res. 2017;23(12):3168\u201380.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"448_CR27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5858\/133.3.413","volume":"133","author":"S Yachida","year":"2009","unstructured":"Yachida S, Iacobuzio-Donahue CA. The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med. 2009;133(3):413\u201322.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"448_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cllc.2013.10.001","volume":"15","author":"DR Gandara","year":"2014","unstructured":"Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, et al. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014;15(1):1\u20136.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"448_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/2326-6066.CIR-16-0287","volume":"5","author":"DY Wang","year":"2017","unstructured":"Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, et al. Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma. Cancer Immunol Res. 2017;5(5):357\u201362.","journal-title":"Cancer Immunol Res"},{"key":"448_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329\u201360.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"448_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/2159-8290.CD-17-1320","volume":"8","author":"W Pao","year":"2018","unstructured":"Pao W, Ooi CH, Birzele F, Ruefli-Brasse A, Cannarile MA, Reis B, et al. Tissue-specific immunoregulation: a call for better understanding of the \u201cimmunostat\u201d in the context of cancer. Cancer Discov. 2018;8(4):395\u2013402.","journal-title":"Cancer Discov"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0448-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0448-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0448-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:48:02Z","timestamp":1662479282000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0448-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["448"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0448-1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]},"assertion":[{"value":"5 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient described in this case signed a case report informed consent form which is available for review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient consented to publication of the case report.Informed written consent was obtained from patient for publication of this case. Consent is available upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Eileen M. O'Reilly\u00a0(EOR):\u00a0Research Funding Celgene, Sanofi, ActaBiologica, AstraZenica, Silenseed, Genentech-Roche. Consulting: Targovax, Celgene, Bayer.\u00a0Matthew D. Hellman (MDH) receives research funding from Bristol-Myers Squibb; is paid consultant to Merck, Bristol-Myers Squibb, AztraZeneca, Genentech\/Roche, Janssen, Nektar, Syndax, Mirati, and Shattuck Labs; receives travel support\/honoraria from AztraZeneca and BMS; and a patent has been filed by MSK related to the use of tumor mutation burden to predict response to immunotherapy (PCT\/US2015\/062208), which has received licensing fees from PGDx.Luis A. Diaz (LAD) is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics. LAD holds equity in PapGene, Personal Genome Diagnostics (PGDx) and Phoremost. He is a paid consultant for Merck, PGDx and Phoremost. LAD is an inventor of licensed intellectual property related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy (WO2016077553A1) from Johns Hopkins University. These licenses and relationships are associated with equity or royalty payments to LAD. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. In addition, in the past 5 years, LAD has participated as a paid consultant for one-time engagements with Caris, Lyndra, Genocea Biosciences, Illumina and Cell Design Labs. Jedd Wochok (JD) Consultant for: Adaptive Biotech; Advaxis; Amgen; Apricity; Array BioPharma; Ascentage Pharma;Astellas; Beigene; Bristol Myers Squibb; Celgene; Chugai; Elucida; Eli Lilly; F Star; Genentech; Imvaq; Kleo Pharma; MedImmune; Merck; Neon Therapuetics; Ono; Polaris Pharma; Polynoma; Psioxus; Puretech; Recepta; Trieza; Sellas Life Sciences; Serametrix; Surface Oncology; Syndax. Research support: Bristol Myers Squibb; Medimmune; Merck Pharmaceuticals; Genentech. Equity in: Potenza Therapeutics; Tizona Pharmaceuticals; Adaptive Biotechnologies; Elucida; Imvaq; Beigene; Trieza.Zsofia Stadler (ZK): Immediate Family Member, Ophthalmology Consulting\/Advisory Role: Allergan, Adverum Biotechnologies, Alimera Sciences, Biomarin, Fortress Biotech, Genentech, Novartis, Optos, Regeneron, Regenxbio, Spark Therapeutics. The\u00a0other authors (ZIH, MV, JS) declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"127"}}